TECX

Tectonic Therapeutic, Inc.

Healthcare
Biotechnology
$392M market cap

Forecast run · Oct 29, 2026Upside rank 261 of 3,186

Model Signal

ForecastQ Daily Probabilities

52.9%

26.4%

38.3%

Analyst Consensus

Recommendation1.80/5 Buy

Last price$20.07

Price target$62.33

Implied move+210.6%

Analysts5

ForecastQ Portfolios

Healthcare Healthcare signal →

Company Profile

Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.